Today, Nagarro, a global digital engineering leader, presented its unaudited financial numbers for Q3 2024 and released its nine-month statement. In ...

Markets initially responded well to CVS’s Q3 results. In the quarter ... Former Covid supplier champ Moderna (MRNA) closed ...

Entered two new OEM programs through agreement with Level 4 platform partner with expected SOP in 2026; Met operational target of 2-3 additional customer programs in ...

Headquartered in Cambridge, Massachusetts, Moderna, Inc. (MRNA) is a biotechnology company specializing in messenger RNA ...

Moderna (MRNA) is up more than +3% after reporting Q3 Covid-19 vaccine revenue of $1.8 billion, which is stronger than the consensus of $1.2 billion. Lyft (LYFT) is up more than +29% after reporting ...

PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced its financial results for the third quarter of 2024 ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

On NVAX's third-quarter earnings call, investors will likely seek updates on management???s ongoing discussions with the FDA ...

Healthcare sector earnings report summary: 14 companies beat profit estimates, with major players like Viatris, Gilead ...

Even though the company surprised analysts by reporting net income of $13 million (up from a $3.63 billion net loss in Q3 ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Barclays lowered the firm’s price target on Moderna (MRNA) to $111 from $125 and keeps an Overweight rating on the shares. The ...